Skip to main content
NCD 250.5 · version 1

NCD 250.5: Dermal Injections for the Treatment of Facial Lipodystrophy Syndrome (LDS)

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database NCDs: API snapshot September 27, 2026 (effective September 20, 2026). Next CMS release: weekly, every Thursday.

Medicare Coverage Database NCDs: the loaded version is API snapshot September 27, 2026, and the CMS schedule called for a newer one from October 1, 2026. Verify figures against the current CMS publication until this reference is rebuilt; pages built on it are withdrawn from search indexing until then.

Key facts for NCD 250.5

Benefit category
Physicians' Services
Effective date
03/23/2010
Implemented 07/06/2010
Transmittal
Transmittal 122
Versions published
1
Manual section
250
Skin, NCD Manual (Pub. 100-03) chapter 1 part 4

TL;DR

NCD 250.5 sets Medicare's national policy for dermal injections for the treatment of facial lipodystrophy syndrome (lds) under the benefit category "Physicians' Services", effective 03/23/2010 and implemented 07/06/2010. Effective for claims with dates of service on and after March 23, 2010, dermal injections for LDS are only reasonable and necessary using dermal fillers approved by the Food and Drug Administration (FDA) for this purpose, and then only in HIV-infected… It has been revised once since publication and binds every Medicare Administrative Contractor nationally.

Item or service described

A. General

Treatment of persons infected with the human immunodeficiency virus (HIV) or persons who have Acquired Immune Deficiency Syndrome (AIDS) may include highly active antiretroviral therapy (HAART). Drug reactions commonly associated with long-term use of HAART include metabolic complications such as, lipid abnormalities, e.g., hyperlipidemia, hyperglycemia, diabetes, lipodystrophy, and heart disease. Lipodystrophy is characterized by abnormal fat distribution in the body.

The LDS is often characterized by a loss of fat that results in a facial abnormality such as severely sunken cheeks. The patient’s physical appearance may contribute to psychological conditions (e.g., depression) or adversely impact a patient’s adherence to antiretroviral regimens (therefore jeopardizing their health) and both of these are important health-related outcomes of interest in this population. Therefore, improving a patient’s physical appearance through the use of dermal injections could improve these health-related outcomes.

Indications and limitations of coverage

B. Nationally Covered Indications

Effective for claims with dates of service on and after March 23, 2010, dermal injections for LDS are only reasonable and necessary using dermal fillers approved by the Food and Drug Administration (FDA) for this purpose, and then only in HIV-infected beneficiaries when LDS caused by antiretroviral HIV treatment is a significant contributor to their depression.

C. Nationally Non-Covered Indications

• Dermal fillers that are not approved by the FDA for the treatment of LDS.

• Dermal fillers that are used for any indication other than LDS in HIV-infected individuals who manifest depression as a result of their antiretroviral HIV treatments.

D. Other

N/A

(This NCD last reviewed March 2010.)

Text reproduced from the CMS Medicare Coverage Database record for NCD 250.5 version 1. View the original on cms.gov.

Local policies that build on this NCD

3 active Local Coverage Determinations cite NCD 250.5 among their related national policies. An LCD may not conflict with the national determination; read it for the contractor's documentation and coding detail in that jurisdiction.

  • Cosmetic and Reconstructive Surgery (L39051) · Wisconsin Physicians Service Insurance Corporation
  • L33428 Cosmetic and Reconstructive Surgery · Palmetto GBA
  • L39506 Cosmetic and Reconstructive Surgery · CGS Administrators, LLC

How MACs bill NCD 250.5

A National Coverage Determination states the policy; the Medicare Administrative Contractors publish the articles that turn it into claim edits. 2 current articles in the Medicare Coverage Database name NCD 250.5, 2 of them with a covered ICD-10-CM list, from 2 contractors. The lists can differ by contractor even though the NCD is national, because each MAC codes the policy for its own claims system; check the article of the contractor that processes the claim.

Contractors with articles that implement NCD 250.5
ContractorArticles
CGS Administrators, LLCA59299
Wisconsin Physicians Service Insurance CorporationA58774

A58774: Billing and Coding: Cosmetic and Reconstructive Surgery

Billing and Coding, effective 2026-06-25 · Wisconsin Physicians Service Insurance Corporation (05101, 05102, 05201, 05202, 05301, 05302, 05401, 05402, 05901, 08101, 08102, 08201, 08202) · CMS record

222 covered ICD-10-CM codes in 10 groups, 1 non-covered; 72 procedure codes: 11920, 11921, 11922, 11950, 11951, 11952, 11954, 15775, 15776, 15780, 15781, 15782 and 60 more. Local policy: L39051 Cosmetic and Reconstructive Surgery. Check a diagnosis for 11920.

First covered codes: C44.501 Unspecified malignant neoplasm of skin of breast; C44.511 Basal cell carcinoma of skin of breast; C44.521 Squamous cell carcinoma of skin of breast; C44.591 Other specified malignant neoplasm of skin of breast; C50.011 Malignant neoplasm of nipple and areola, right female breast; C50.012 Malignant neoplasm of nipple and areola, left female breast; …

A59299: Billing and Coding: Cosmetic and Reconstructive Surgery

Billing and Coding, effective 2025-11-27 · CGS Administrators, LLC (15101, 15102, 15201, 15202) · CMS record

219 covered ICD-10-CM codes in 9 groups, 1 non-covered; 76 procedure codes: 11920, 11921, 11922, 11950, 11951, 11952, 11954, 15775, 15776, 15780, 15782, 15783 and 64 more. Local policy: L39506 Cosmetic and Reconstructive Surgery. Check a diagnosis for 11920.

First covered codes: C44.501 Unspecified malignant neoplasm of skin of breast; C44.511 Basal cell carcinoma of skin of breast; C44.521 Squamous cell carcinoma of skin of breast; C44.591 Other specified malignant neoplasm of skin of breast; C50.011 Malignant neoplasm of nipple and areola, right female breast; C50.012 Malignant neoplasm of nipple and areola, left female breast; …

Coverage analysis history

CMS opens a national coverage analysis (NCA) to create or reconsider an NCD; the analysis carries a CAG tracking number, the evidence review and the decision memo. The Medicare Coverage Database links one analysis to NCD 250.5, listed here in the order CMS opened them (by NCA record number). A reconsideration ("Recon") revisits an earlier decision; an analysis whose status is open is still in progress.

  1. CAG-00412N Dermal injections for the treatment of facial lipodystrophy syndrome (FLS) (New, Closed)

Revision history

09/2025 - Transmittal 13383 issued August 26, 2025, is being rescinded and replaced by Transmittal 13401,

dated September 9, 2025, to add a new attachment to ensure the functionality of the NCD zip URL is working properly and to update the Policy section. All other information remains the same.

The purpose of this Change Request (CR) is to provide a quarterly maintenance update of ICD-10 coding conversions and other coding updates specific to National Coverage Determinations (NCDs). ( TN 13401 ) (CR14194)

12/2015 - This change request (CR) is the 3rd maintenance update of ICD-10 conversions/updates specific to national coverage determinations (NCDs). The majority of the NCDs included are a result of feedback received from previous ICD-10 NCD CR7818, CR8109, CR8197, CR8691, & CR9087. Some are the result of revisions required to other NCD-related CRs released separately that included ICD-10 coding. Implementation date: 01/04/2016 Effective date: 10/1/2015. ( TN 1580 ) (CR9252)

08/2015 - This change request (CR) is the 3rd maintenance update of ICD-10 conversions/updates specific to national coverage determinations (NCDs). The majority of the NCDs included are a result of feedback received from previous ICD-10 NCD CR7818, CR8109, CR8197, CR8691, & CR9087. Some are the result of revisions required to other NCD-related CRs released separately that included ICD-10 coding.

These updates do not expand, restrict, or alter existing coverage policy. Implementation date: 01/04/2016 Effective date: 10/1/2015. ( TN 1537 ) (CR 9252)

05/2014 - CMS translated the information for this policy from ICD-9-CM/PCS to ICD-10-CM/PCS according to HIPAA standard medical data code set requirements and updated any necessary and related coding infrastructure. These updates do not expand, restrict, or alter existing coverage policy. Implementation date: 10/06/2014 Effective date: 10/1/2015. ( TN 1388 ) ( TN 1388 ) (CR 8691)

09/2012 - CMS translated the information for this policy from ICD-9-CM/PCS to ICD-10-CM/PCS according to HIPAA standard medical data code set requirements and updated any necessary and related coding infrastructure. These updates do not expand, restrict, or alter existing coverage policy. Implementation date: 01/07/2013 Effective date: 10/1/2015. ( TN 1122 ) ( TN 1122 ) (CR 7818)

06/2010 - Effective for claims with dates of service on or after March 23, 2010, dermal injections for facial LDS are only reasonable and necessary using dermal fillers approved by the Food and Drug Administration for this purpose, and then only in HIV-infected beneficiaries who manifest depression secondary to the physical stigma of HIV treatment. Effective date: 03/23/2010 Implementation date: 07/06/2010 TN 122 (CR6953)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

For teams evaluating QuickIntell software

Evaluate a coverage-review workflow around NCD 250.5

Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — NCD 250.5

What does NCD 250.5 cover?

Effective for claims with dates of service on and after March 23, 2010, dermal injections for LDS are only reasonable and necessary using dermal fillers approved by the Food and Drug Administration (FDA) for this purpose, and then only in HIV-infected beneficiaries when LDS caused by antiretroviral HIV treatment is a significant contributor to their depression. The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 250.5 take effect?

The current version (1) is effective 03/23/2010, implemented 07/06/2010, published in transmittal 122. This is the only published version.

Does a Local Coverage Determination override NCD 250.5?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.